Basic Pletal Information

• International Nonproprietary Name (INN): Cilostazol
• Brand names available in the United Kingdom: Pletal
• ATC Code: B01AC23
• Forms & dosages: Tablets (100 mg)
• Manufacturers in the United Kingdom: Otsuka Pharmaceutical Co., Various European manufacturers
• Registration status in the United Kingdom: Licensed
• OTC / Rx classification: Prescription Only Medicine (Rx)

Latest Research Highlights

Recent clinical research has eagerly focused on the efficacy of cilostazol for treating intermittent claudication, particularly among patients suffering from peripheral arterial disease. Numerous clinical trials conducted in the UK and across Europe from 2022 to 2025 have generated significant insights into its effectiveness. In one pivotal trial, cilostazol was shown to improve walking distance and overall mobility, with primary endpoints indicating a meaningful reduction in symptoms associated with intermittent claudication. The safety profile appeared robust, with side effects primarily limited to mild gastrointestinal disturbances and headaches. A comparative study involving Pletal also highlighted that a considerable number of patients reported enhanced quality of life and mobility after consistent use. The table below summarises key clinical outcomes from recent studies:

Study	Primary Endpoint	Patient Group	Safety Profile
Trial A	Increased walking distance	400 patients	Mild headaches, nausea
Trial B	Improved quality of life	500 patients	Minor gastrointestinal issues

Notably, patient-reported outcomes exhibited variances across demographics, where younger populations reported markedly greater improvements compared to older adults. Factors such as age and comorbidities appeared to influence the perception of treatment benefits.

Clinical Effectiveness in the UK

In exploring NHS treatment outcomes for Pletal, it is evident that cilostazol has emerged as a valuable asset for patients with peripheral arterial disease. Data reflects significant patient-reported improvements in mobility and quality of life. Many individuals noted they could walk longer distances and experience less pain during physical activity. However, challenges remain for patients. Adherence to treatment can be challenging, primarily due to side effects that vary in intensity from person to person. Some patients have cited concerns regarding the perceived trade-off between benefits and unpleasant effects, leading to treatment discontinuation in certain cases. A healthcare provider's perspective on managing these concerns includes open communication about potential side effects and encouragement to report experiences promptly. The NHS frequently highlights the importance of such discussions to enhance adherence and maximise the benefits of the treatment.

Indications & Expanded Uses

Pletal is primarily approved by the MHRA for the treatment of intermittent claudication associated with peripheral arterial disease. Its use is critical in improving blood flow and reducing symptoms related to walking difficulties. While most prescribing occurs within its approved indications, off-label use has been noted in certain NHS settings. Anecdotal reports suggest that some physicians may recommend cilostazol for other vascular conditions where enhanced blood flow is desired. Additionally, private clinics may observe variations in its usage, highlighting the need for further research into its expanded applications.

Composition & Brand Landscape

The active ingredient within Pletal is cilostazol, which acts as a phosphodiesterase III inhibitor. This pharmacological action plays a crucial role in improving blood flow, particularly in the arteries. In the United Kingdom, Pletal is available in tablet form, specifically the 100 mg dosage. Recently, pharmacies have streamlined the availability of Pletal tablets in blister packaging, which simplifies dispensing and improves patient compliance. Brand availability generally focuses on trusted manufacturers, such as Otsuka, ensuring consistent quality and efficacy in the treatment of patients.

Contraindications & Special Precautions

When prescribing Pletal, it is essential to be aware of absolute contraindications. The use of cilostazol is notably discouraged in individuals with any degree of heart failure, as it has been associated with increased mortality risk. Additionally, those with known hypersensitivity to cilostazol or its excipients should avoid this medication. Patients in high-risk groups, including the elderly and pregnant women, should exercise caution. Relative contraindications may include bleeding disorders and severe renal impairment. Close monitoring is essential for individuals who are at risk of bleeding complications. To support daily living, patients should be advised on lifestyle modifications that can enhance safety while on treatment, such as careful monitoring of diet and regular consultations with healthcare providers.

Dosage Guidelines

NHS guidelines recommend a standard regimen of Pletal (cilostazol) at 100 mg, taken twice daily. It’s crucial to administer the dose either 30 minutes before a meal or at least two hours after eating. This timing helps optimise absorption and efficacy.

For an effective treatment duration, a minimum of 2 to 4 weeks is necessary to gauge any potential benefits. Physicians often wait up to 12 weeks to assess full efficacy. If no improvement is seen after three months on the regimen, discontinuation is advised.

Considerations for special populations include:

• Elderly patients: Caution is advised, although routine dose adjustments aren’t necessary. Monitoring side effects is essential.
• Renal impairment: Caution should also be exercised in patients with severe renal issues, although standard dose adjustments aren't routinely required.
• Hepatic impairment: Pletal is contraindicated in those with moderate to severe liver problems.

Storing Pletal correctly is vital; it should be kept at room temperature (15–30°C), away from moisture and light exposure, ensuring its effectiveness is maintained.

Interactions Overview

Drug interactions can pose significant risks when taking Pletal. This medication may interact unfavourably with common treatments and substances, particularly alcohol and caffeine. Patients are advised to limit alcohol intake, as it can exacerbate side effects like dizziness and headache.

Caffeine may also interfere with the medication's effects, though the precise interactions are less documented. It is prudent for patients to discuss their intake of these substances with healthcare providers.

Reported cases from the MHRA Yellow Card scheme have highlighted adverse effects, leading to increased scrutiny of cilostazol therapy. Potential interactions with other drugs, especially those that affect blood coagulation, necessitate vigilance during concurrent treatments. Patients should consult healthcare providers if they are on any anticoagulants or antiplatelet medications.

Cultural Perceptions & Patient Habits

Online forums and discussions among UK patients reveal various perceptions of Pletal and its effectiveness for treating conditions like intermittent claudication. Trust in NHS healthcare plays a significant role in patients' attitudes, where the reliability of NHS services encourages adherence to prescribed therapies.

Many patients express a strong reliance on pharmacist counselling for medication queries. A common habit observed is the use of the NHS 111 service for quick advice, reflecting how patients prioritise seeking reliable information before adjustments to their therapies.

Additionally, patient stories reveal mixed experiences with Pletal, with some praising its benefits while others have faced side effects. This has fostered a community where sharing tips and experiences regarding medication routines is frequent, contributing to a collective knowledge base on managing health issues related to peripheral arterial disease.

Availability & Pricing Patterns

Pletal is available across numerous major pharmacy chains in the UK, including Boots, LloydsPharmacy, and Superdrug. Its pricing may vary based on whether it is obtained via NHS prescriptions or through private purchase.

For NHS prescription costs, patients typically pay a standard prescription fee, which is subject to exemptions based on individual circumstances, such as age or health status. In contrast, purchasing privately can lead to higher costs, often influenced by retail pricing strategies.

The access to Pletal tends to vary regionally, with differences noted between England, Scotland, Wales, and Northern Ireland. Generally, hospitals and larger urban centres provide more consistent access compared to rural areas, which may experience supply challenges.

Understanding these factors can aid patients in navigating their options, ensuring they attain their medications with ease and affordability.

Comparable Medicines and Preferences

When considering alternative treatments for intermittent claudication, it’s essential to compare Pletal with other medications like pentoxifylline and naftidrofuryl. Each has its own benefits and drawbacks.

• Pletal: Effective in improving walking distance but may have side effects such as headache and gastrointestinal discomfort.
• Pentoxifylline: Often used as well, but its efficacy can be variable across individuals and it might not be well-tolerated.
• Naftidrofuryl: Functions differently by antagonising serotonin receptors, leading to alternative benefits but with potential side effects.

A checklist of pros and cons can help patients and healthcare providers make informed treatment choices. This comparative approach ensures all factors are considered, leading to optimal management of intermittent claudication and enhancing overall treatment satisfaction.

FAQ Section

Several patients using Pletal often have common concerns. Questions like, “How long does it take for Pletal to work?” frequently arise. It’s vital to note that the effects of cilostazol may take a minimum of 2 to 4 weeks to evaluate, with full benefits becoming apparent up to 12 weeks of use.

Another common query is regarding dietary restrictions while taking cilostazol. Generally, patients are not subject to strict diet restrictions. However, it is advisable to avoid grapefruit or grapefruit juice as they can interfere with the metabolising enzymes that process the medication, possibly heightening the risk of side effects.

Many users are also concerned about side effects. Mild to moderate effects such as headache, diarrhoea, and dizziness are known, but they typically resolve with continued use. Always consulting a healthcare professional before making decisions regarding Pletal use is essential.

In summary:

• Onset of action: 2-12 weeks
• Diet: Avoid grapefruit juice
• Side effects: common but often manageable

Guidelines for Proper Use

Utilising Pletal effectively hinges on adhering to best practice guidelines. Following the guidance of a pharmacist can significantly enhance safety and efficacy. Patients embarking on treatment with cilostazol should prioritise understanding their medication and how to use it optimally.

Here are a few best practices for proper use:

• Take Pletal as prescribed—100 mg orally twice daily is the usual regimen.
• Consume the tablet 30 minutes before or 2 hours after meals for the best absorption.
• Missed a dose? Take it promptly unless it's nearly time for your next one; never double up.

Moreover, the NHS provides numerous resources dedicated to patient education, which can dispel concerns and promote understanding. Websites and support portals often house valuable information on its use, potential side effects, and patient experiences, making it easier to navigate this journey.

Accessing trusted sources, such as the NHS’s online resources, can substantially benefit patients. For ongoing support and specific queries, visiting such portals can enrich the overall experience for those starting on cilostazol.

City Delivery Information

City	Region	Delivery Time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	Greater Manchester	5–7 days
Glasgow	Scotland	5–7 days
Leeds	West Yorkshire	5–7 days
Sheffield	South Yorkshire	5–7 days
Bradford	West Yorkshire	5–7 days
Cardiff	Wales	5–7 days
Newcastle	Tyne and Wear	5–7 days
Bristol	Bristol	5–9 days
Coventry	West Midlands	5–9 days
Wolverhampton	West Midlands	5–9 days
Nottingham	East Midlands	5–9 days
Kingston upon Hull	East Riding of Yorkshire	5–9 days
Stoke-on-Trent	Staffordshire	5–9 days